Researchers identified cathepsin B and L as essential enzymes for Ebola virus reproduction, shedding light on its infection mechanism. Inhibiting these enzymes could lead to the development of a broad-spectrum antiviral therapy against multiple hemorrhagic fever viruses.
Researchers found that 12.9% of wild chimpanzees carry Ebola virus antibodies, indicating regular contact with the animal reservoir and non-fatal infections. Dogs also carry the virus, with high antibody prevalence near epidemic foci, suggesting they could become a potential source of infection for humans.
Research reveals that Ebola viruses can spread from wild animals to humans through handling or consuming animal carcasses. This finding emphasizes the need for improved awareness and monitoring of wildlife in Central Africa to prevent future outbreaks.
Experts say doctors need extensive training to prepare for bioterrorism threats, which can involve an incubation period of days or weeks. Doctors will be expected to recognize rare conditions and take appropriate action, balancing suspicion with hysteria.
The Lancet editorial advocates for free access to genome data, highlighting its benefits in accelerating research on diseases such as SARS. This open-access policy promotes international cooperation, trust, and altruism, offering a compelling alternative to bioweapons.
A possible new Ebola outbreak could lead to the deaths of over 20,000 western lowland gorillas within months if confirmed. The park is home to an estimated 30,000 gorillas, and a study suggests that when Ebola affects an area, more than 80% of great apes die from the disease.
Dr. Peter Jahrling has been recognized by the American Association for the Advancement of Science (AAAS) as a Fellow for his contributions to vaccine development and medical defense against infectious diseases. He is credited with advancing research on filovirus and poxvirus threats.
The Ebola virus has unleashed several lethal epidemics in Central Africa, leading to haemorrhagic fever and high mortality rates. The virus is transmitted by direct contact with infected animals or their carcasses, resulting in a rapid decline in great ape populations.
A study by Wildlife Conservation Society reveals that simultaneous Ebola outbreaks consist of multiple viral strains originating from different areas. The authors recommend establishing a monitoring network to look for dead and dying large animals as an early warning system to minimize damage to both people and wildlife.
A new drug, rNAPC2, has shown promising results in treating Ebola by slowing coagulopathy and death in primates. The treatment targets the disease process rather than replicating the virus, offering a potential breakthrough in combating the deadly disease.
Researchers have discovered a potential treatment for Ebola, showing a 33% survival rate among treated macaques. The study found that inhibiting blood coagulation pathways prolonged survival time and improved health outcomes.
Researchers at USAMRIID have developed Ebola virus-like particles (VLPs) that induce both cell-mediated and humoral immunity in mice, providing 100% protection against lethal challenge. The VLPs, resembling infectious viral particles without genetic material, offer a promising vaccine platform for Ebola and other viruses.
The first human trial of a DNA Ebola vaccine opened at the NIH Clinical Center in Bethesda. Twenty-seven volunteers will receive either the investigational vaccine or a placebo injection over two months and be followed for one year.
Scientists at NIAID and USAMRIID developed a prime-boost vaccine strategy that protects monkeys from Ebola infection. The boost alone shows promise in offering quick but weaker immune response.
Scientists create hybrid virus that can attach to lung cells' top surface, allowing healthy genes to enter and correct genetic defects associated with cystic fibrosis. The new approach increases production of viral particles, a crucial step towards preclinical studies.
A study published in Nature reveals that wild chimpanzee and gorilla populations have declined by over 50% in the past few decades, with an estimated 80% decline expected within 30 years. The researchers attribute this to illegal hunting and Ebola outbreaks, highlighting the need for improved anti-poaching laws and Ebola research.
A recent study warns of a dramatic decline in western equatorial Africa's great ape populations, with gorillas and chimpanzees facing nearly 60% decline since 1983. The research highlights the urgent need for aggressive investments in Ebola prevention, law enforcement, and protected area management to ensure their survival.
Researchers discover protein from blue-green algae that inhibits both HIV and Ebola virus infections, potentially leading to new treatments. The protein works by binding to the outside of the viruses and blocking them from entering cells.
A community-based care model has been shown to be effective in treating multidrug-resistant tuberculosis (MDR-TB) in resource-poor nations. The study found that 83% of patients who completed at least four months of therapy had probable cures, exceeding the best reported U.S. cure rate.
Researchers found a biochemical structure similarity between the Ebola virus outer protein shell and retroviruses carried by birds, suggesting possible bird transmission. This discovery raises health concerns for humans and encourages officials to be vigilant.
Researchers at Purdue University have simplified the outer shell of the Ebola virus, making it easier to produce in a lab and delivering genes to defective cells. This breakthrough could lead to treatments for diseases like cystic fibrosis and lung cancer.
The western chimpanzee is critically endangered with only 4% of its original population remaining. Conservation efforts are underway to address threats such as agricultural development, logging, and the bush meat trade. The action plan provides a roadmap for halting or reversing the decline in chimpanzee numbers in West Africa.
Hemorrhagic fever viruses, such as Ebola and Marburg, pose significant threats due to their high mortality rates and lack of effective treatments. The report recommends improving diagnostic capacity, developing rapid tests, and researching new antiviral medications to counter these threats.
Researchers demonstrate that Ebola and Marburg viruses rely on lipid rafts in the cell membrane to gain entry and assemble. This finding opens up potential therapeutic avenues against these deadly pathogens.
Researchers mapped areas of Africa at risk for RVF outbreaks, identifying conditions necessary for breeding mosquitoes that transmit the virus. Satellite data also suggested a link between dry to wet changes in tropical regions and Ebola outbreaks.
Researchers have developed a new genetic technique that can deliver a knockout blow to the Asthma Virus by targeting its RNA. The technique, called post-translational gene silencing, uses specific siRNA molecules to block viral protein production and suppress virus replication.
Researchers at Dana-Farber Cancer Institute have developed a method for detecting unknown microorganisms in human tissue, leveraging DNA sequencing data. The technique, called computational subtraction, has shown promise in identifying novel infectious agents in mysterious chronic diseases.
A Yale University study found that tracking unexplained illness and death can aid in identifying emerging infectious diseases. The research compared two surveillance methods, finding prospective surveillance to be 32% more sensitive than retrospective evaluation.
Gladstone researchers identified a key protein on cells that can be targeted to block Ebola and Marburg virus entry. This finding offers new hope for developing treatments against these deadly viruses.
The article highlights the risk of biological warfare, citing the existence of frozen stocks of smallpox virus and conventional biological agents. Genetic engineering also poses a threat, as microbiologists' knowledge could be used to create novel, deadly pathogens.
Researchers at the University of Pennsylvania have discovered a key protein, VP40, crucial for Ebola's replication cycle. This finding holds promise for developing novel antiviral drugs to stop the spread of the deadly disease.
A team of researchers at NIH has developed a novel vaccine that prevents Ebola virus infection in monkeys, offering a promising new approach to protecting humans. The vaccine induces strong anti-Ebola immune responses and protects against lethal doses of the virus.
Researchers at Penn State College of Medicine have identified ubiquitin as crucial to budding, a process allowing viruses to exit host cells and infect new ones. The study's findings suggest that ubiquitin plays a key role in the maturation and release of viral particles from the cell surface.
Researchers have identified a viral protein responsible for Ebola-induced internal bleeding. The discovery could lead to the development of targeted antiviral treatments and vaccines to prevent the disease. By understanding how the virus attaches to and enters cells, scientists can design more effective countermeasures.
A new report highlights the significant threat of emerging infectious diseases in wildlife to both human health and global biodiversity. The study reveals that many diseases have spread from domestic animals to wildlife populations through various means, including globalization, animal trade, and environmental changes.
Researchers at Purdue University have identified a protein segment crucial for the infection of cells by retroviruses and other viruses. By replacing just one amino acid in this region, they were able to eliminate fusion between the virus and its host cell. This discovery may lead to novel treatments to block the entry of these viruses.
A new DNA vaccine has been developed to protect North American salmon and trout farms from a major disease, with successful trials showing 90% reduction in mortality. The vaccine works by introducing DNA containing the gene for one of the viral proteins, which is then taken up by cells and produces the protein to prime the immune system.
Scientists discovered a common viral harpoon protein structure among measles, mumps and respiratory syncytial viruses. This finding suggests that these viruses may be related to HIV, influenza and Ebola viruses, potentially leading to the development of new drugs.
Researchers at Northwestern University discovered a common ancestor among viruses that cause measles, mumps, and respiratory infections in infants and HIV, influenza, and Ebola. The study found a similar entry mechanism among these viruses, suggesting new approaches to blocking infection.
The report highlights the resurgence of infectious and parasitic diseases, including exotic ones like Ebola and dengue hemorrhagic fever. The authors call for strengthened infection control precautions, rapid diagnostic tests, and improved public education to combat these diseases.